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Abstract
The African Organization for Research and training in Cancer (AORTIC) bases the following position statements
on a critical appraisal of the state on cancer research and cancer care in Africa including information on the
availability of data on cancer burden, screening and prevention for cancer in Africa, cancer care personnel,
treatment modalities, and access to cancer care.
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Background
Cancer is a major public health concern In Africa
Cancer is a leading cause of death worldwide. About half
of the annual incident cancer cases occur in the develop-
ing world. There were an estimated 14.1 million new
cancer cases and 8.2 million cancer related deaths in
2012 [4]. Of these, there were 715,000 incident cancer
cases and 542,000 deaths in Africa, with increasing inci-
dence of breast and prostate cancers. The incidence of
cancer is therefore increasing worldwide and the con-
tinuing global demographic and epidemiologic transi-
tions signal an ever-increasing cancer burden over the
next decades, particularly in low- and middle-income
countries (LMIC). Africa is expected to carry a major
cancer burden by year 2030 [4]. Incidence rates of 1.27
million with 0.97 million deaths are estimated in 2030
for Africa.
Cancer in Africa has many unique features. As shown
in Table 1, the leading cancers in Africa include many of
those that are common around the world, but also in-
clude cancers that are less common in high-income
countries and reflect patterns of cancer more commonly
seen in low- and middle-income countries (LMIC). In
addition, the distribution of cancer types varies substan-
tially within Africa, and these differ compared to the
cancer type distribution in other parts of the world, with
a high proportion of infection related cancers in many
areas in Africa [8]. In men, prostate cancer is the leading
cancer in most parts of Africa, similar to that in many
other parts of the world. However, liver cancer is the
leading cancer in large sections of West Africa, Kaposi
Sarcoma is the leading cancer in Southeast Africa, and
esophageal cancer is the leading cancer in Botswana. In
addition, while breast cancer is the leading cancer in
women in many parts of Africa, cervical cancers pre-
dominate in West Africa and parts of East and Central
Africa [4]. Kaposi’s sarcoma was the second largest con-
tributor to the cancer burden in sub-Saharan Africa. The
AFs for infection varied by country and development
status—from less than 5% in the USA, Canada,
Australia, New Zealand, and some countries in western
and northern Europe to more than 50% in some coun-
tries in sub-Saharan Africa [8].
Cancer in Africa
Unlike other parts of the world, for many cancers, inci-
dence and mortality rates in Africa are very similar
(Fig. 1). Five-year survival trends have shown wide dif-
ferences across the continents with variably significant
improvements in some cancers in different developed
countries but much less so in developing countries [3].
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The high case-fatality rate in Africa can be attributed to
a wide range of factors, including the following:
Delayed diagnosis Lack of early and accurate diagnosis
is a challenge to appropriate care. More than 80% of
patients in Africa are diagnosed at advanced stages of
cancer. Radiology facilities are too few to diagnose the
population in need [6]. Inadequate pathology leads to
wrong diagnosis and patients may receive inappropriate
treatment [1, 2]. Scarcity of care providers and re-
searchers is a problem in pathology training, and many
countries have fewer than one pathologist for every mil-
lion people [2]. Opportunities for prevention are widely
under-utilized. For example, cervical cancer is the lead-
ing cause of cancer death for women in 40 of 48 coun-
tries in sub-Saharan Africa, yet many countries have
limited screening services (PAP test) and HPV
vaccination.
Access to healthcare Problems and challenges for can-
cer control in Africa exist at every step of the patient’s
journey. Awareness for cancer is lower in comparison
with other infectious disease priorities. Cancer is often
seen as a disease caused by spiritual curses, and as such
cancer cases are often referred to healers or shamans for
traditional or spiritual treatment. Health care providers
in rural areas lack training on cancer, often misdiagnos-
ing cancer as other illness. Lack of data on cancer preva-
lence and trends in Africa and historical focus on
communicable diseases decrease government efforts on
cancer research and treatment.
Availability of treatment modalities High quality treat-
ment is difficult due to limited healthcare sources and
low affordability. In 2015, the estimated shortage of
health care professionals (792,000) will cost $2.2+ billion
annually in the 31 African countries [10, 11]. The
current number of physicians practicing in Africa
(145,000) represents 5% of the European total
(2,877,000). Treatment access is also limited: ~22% of
the 54 African countries have no access to anti-cancer
therapies. Barriers to treatment include significant out-
of-pocket expenses. Out-of-pocket health expenditure is
estimated to push many people globally into dire poverty
when treatment costs are substantially higher than in-
come. Finally, there is a constant threat to the clinician
pool due to ‘brain drain’. More than half of 168 medical
schools surveyed reported losing between 6 to 18% of
teaching staff to emigration in the last 5 years [7]. It will
be critical to attract African health care personnel to
more attractive settings with better salaries, working
conditions, career paths and support.
Table 1 Leading cancers in men and women in Africa (Source:
Globocan 2012)
Site Deaths Adjusted Ratea Cumulative Riskb
Men
Prostate 42,802 17.0 1.5
Liver 37,012 11.8 1.3
Lung 19,430 7.0 0.8
Kaposi sarcoma 16,343 4.9 0.5
Colorectum 15,102 5.1 0.6
Non-Hodgkin lymphoma 15,021 4.3 0.4
Oesophagus 14,702 5.3 0.6
Stomach 12,000 4.1 0.5
Leukaemia 11,638 3.1 0.3
Bladder 9362 3.5 0.4
Pancreas 6424 2.3 0.3
Lip, oral cavity 6083 2.1 0.2
Brain, nervous system 5415 1.6 0.2
Larynx 4258 1.5 0.2
Kidney 4155 1.1 0.1
Nasopharynx 3478 1.1 0.1
Hodgkin lymphoma 2834 0.8 0.1
Other pharynx 2631 0.9 0.1
Multiple myeloma 2573 0.9 0.1
Melanoma of skin 1543 0.5 0.1
Women
Breast 63,160 17.3 1.8
Cervix uteri 60,098 17.5 2
Liver 19,045 5.6 0.6
Colorectum 14,270 4.2 0.5
Ovary 13,085 3.8 0.4
Non-Hodgkin lymphoma 11,427 2.9 0.3
Oesophagus 10,542 3.3 0.4
Stomach 9801 3.0 0.3
Leukaemia 9483 2.4 0.3
Kaposi sarcoma 9184 2.2 0.2
Lung 7653 2.4 0.3
Pancreas 5280 1.6 0.2
Brain, nervous system 4581 1.2 0.1
Lip, oral cavity 4258 1.3 0.1
Corpus uteri 4030 1.3 0.2
Kidney 4014 0.9 0.1
Thyroid 3979 1.3 0.2
Bladder 3906 1.2 0.1
Gallbladder 2796 0.9 0.1
Multiple myeloma 2494 0.8 0.1
aAge-adjusted rate per 100,000 population
bCumulative Risk ages 0–74 in %
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End of life care End of life care is a particularly critical
domain for cancer control in Africa given the late pres-
entation of many cancers and limited treatment oppor-
tunities. Cancer is diagnosed at such a late stage that
treatment is no longer effective, leaving palliative care as
the only option for reducing suffering. Inaccurate fore-
casting for highly-controlled medications has historically
lead to shortages of critical pain relief options. Home-
based care options are limited for African patients, espe-
cially outside capital cities. Rural families may view
cancer as curse and therefore do not want to treat
patient. Not all rural health facilities are authorized to
stock powerful pain medications necessary to properly
reduce human suffering associated with late stage cancer
Why is cancer research important in Africa?
As described above, the unique pattern of cancers, can-
cer etiologies, and limitations in early detection, diagno-
sis and treatment in Africa suggest that priorities for
cancer control (including prevention and treatment) are
likely to be different than in other parts of the world.
Therefore, strategies for cancer control in Africa require
that data to be generated are relevant to African popula-
tions. Currently, cancer research in Africa is limited in a
number of important ways. First, the number and quality
of cancer registries and of trained cancer registry staff is
inadequate to provide information on the cancer burden
in Africa. Without this basic information, planning for
clinical and public health needs in Africa is not optimal.
Secondly, there are few cancer advocates and trained
community health workers to inform the public and
policy-makers about cancer. Thirdly, the number of
oncologists and other cancer clinical specialists remains
inadequate to deal with the current cancer burden. The
situation doesn’t appear to improve as the projected
number of oncologists and other cancer specialists con-
tinues to fall short in meeting the requirements to con-
trol the growing cancer burden in Africa. There are also
relatively few cancer researchers to generate the know-
ledge base that may be required to create cancer control
strategies in Africa. These include cancer epidemiolo-
gists, statisticians, scientists, public health experts, health
economists, behavioral scientists, and others.
AORTIC has decided to address these problems by
acknowledging that the cancer burden in Africa will
continue to rise, data on cancer in Africa are extremely
limited, there is poor funding for cancer research, there
is inadequate research infrastructure in most of Africa,
and cancer researchers are few, mostly senior people
who are also otherwise engaged in “clinical medicine or
governance.
The AORTIC vision for cancer research in Africa
AORTIC has developed a cancer plan for Africa that
began with the Dakar Declaration in 2011 (http://
www.aortic-africa.org/index.php/news/aortic-dakar-decla
ration-press-release/) and has evolved with the publica-
tion of the Cancer Plan for the African Continent 2013–
2017 (http://www.aortic-africa.org/images/uploads/AOR-
TIC_CANCER_PLAN.pdf). These documents form the
basis for the implementation of cancer control and re-
search efforts by AORTIC in Africa. AORTIC continues
to implement, evaluate, and extend these statements
through its ongoing activities. The AORTIC Research
Committee was formed to lead the planning and imple-
mentation of the cancer research initiatives outlined in
Fig. 1 Age-standardized incidence and mortality rates for the leading cancers in Africa (Source GLOBOCAN 2012)
Ogunbiyi et al. Infectious Agents and Cancer  (2016) 11:63 Page 3 of 6
these two documents. The guiding principles of the
Research Committee were that cancer research in Africa
should be impactful (i.e., able to inform science and clin-
ical practice globally, while informing African public
health and policy needs locally) and sustainable (i.e., led
by Africans involved in global collaborative teams). This
plan is premised on the fact that cancer research pro-
vides the evidence base on which prevention, control,
and treatment strategies must be built. Components of
this plan include improved policy and funding support,
improved knowledge of cancer is Africa, awareness of
cancer burden, clinical oncology infrastructure and im-
proved cancer health systems, and cancer prevention
and control.
The implementation of this plan includes the develop-
ment of regional infrastructure that will foster cancer re-
search; increase the quality and quantity of research
workforce focused on cancer control in Africa; and
promote and support translational research throughout
the cancer control continuum across crosscutting issues,
including communications, surveillance, social determi-
nants of health, genetic testing, decision-making, dis-
semination of evidence-based interventions, quality of
cancer care, epidemiology and measurement.
AORTIC has developed tangible products and activ-
ities to assist in the implementation of the general con-
cepts of this plan. First, AORTIC produced a Handbook
for Cancer Research in Africa that provides a general
outline of Africa-specific research approaches for cancer
[9]. Topics that were identified as being key to the suc-
cess of cancer research in Africa that were included in
this volume were basic research principles, career con-
siderations, developing and maintaining research part-
nerships, responsible conduct of research, research
funding, community engagement research, biosampling
and biobanking, pathology, data management and ana-
lysis, clinical trials, research advocacy, and research
dissemination.
Second, as specified in the cancer plan, AORTIC has
initiated research training workshops on cancer in Af-
rica. The first of these will be held in January 2017 in
Cape Town, South Africa in collaboration with the
American Association for Cancer Research. The target
audience will be both established researchers who wish
to develop cancer-specific projects as well as new inves-
tigators and trainees. The topics identified for the Hand-
book were carried over as the main workshop content
areas.
Third, an African Cancer Research Alliance (ACRA)
has been initiated. The goal of the ACRA is to de-
velop the expertise, resources, and infrastructure that
can lead to impactful investigator-initiated cancer re-
search in Africa. The ACRA will share and develop
research methods and technology that are optimally
suited for research in Africa; create partnerships
among institutions and investigators who can under-
take collaborative research; facilitate research projects
that will impact our understanding of cancer world-
wide and impact clinical service and public health in
Africa. In addition to these immediate goals, ACRA
will improve research infrastructure in Africa, estab-
lish a trained African cancer research workforce, and
generate data that impact on the health of popula-
tions in Africa and worldwide. The implementation of
ACRA will involve identification of research “hubs”
that have general capacity for cancer research includ-
ing epidemiology, laboratory methods, clinical cap-
acity, and other features. Characteristics of these hubs
are being developed and hubs will be identified
throughout Africa.
There are a number of examples of research networks
upon which the ACRA network will be built, and from
which research hubs could be identified. Three existing
prostate cancer networks serve as a focus around which
urological cancer research may be formed: the Men of
African Descent and Carcinoma of the Prostate (MAD-
CaP) network, The African Caribbean Cancer Consor-
tium (AC3), and the Prostate Cancer Transatlantic
Consortium (CaPTC). Similarly, the African Consortium
on Cervical Cancer Control Research (COFAC-Col) and
the African Breast Cancer Consortium can serve as foci
around which ACRA networks and hubs will be
established.
Finally, AORTIC has developed a registry of re-
searchers and research projects through the African
Cancer Research Registry (http://mendel2.med.upenn.
edu:8080/AfricaProject/MapView.jsp). Figure 2 provides
a summary of the countries in which cancer projects
have been identified and included in registry This regis-
try provides the potential for African cancer researchers
to identify related projects and colleagues with similar
interests. The data in this registry are also included in
the Global Cancer Project Map (http://globalonc.org/
Projects/global-cancer-project-map/) developed by Glo-
bal Oncology. Ongoing research initiatives are being
identified and will be included as found. However, in
the future all data will be incorporated directly into
the Global Cancer Project Map, which will serve as
the central repository for this information in the
future.
While ACRA will serve as the AORTIC focus for
the development of cancer research activities in
Africa, it will also strive to work with other existing
partners. These include funders such as the US
National Cancer Institute, the International Union
Against Cancer (UICC), the American Association for
Cancer Research (AACR), and the American Society
for Clinical Oncology (ASCO). In addition, ACRA will
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work with the AORTIC Education and Training Com-
mittee to foster training opportunities as research
capacity is built.
Areas of focus
Data shown in Table 1 identify the leading cancer sites
in Africa. These include prostate, liver, lung cancers and
Kaposi sarcoma in men, and breast, cervical, liver, colo-
rectal and ovarian cancers in women. In addition, child-
hood cancers, many of which are treatable or even
curable, are of interest because of the high rates of mor-
tality that remains for African children diagnosed with
these tumors. The ACRA will focus much of its efforts
in the development of research projects and infrastruc-
ture that address these most common cancers to max-
imally impact on the burden of cancer in Africans.
While the data on cancer incidence and mortality rates
are not as well captured in Africa as in the US, it is clear
from recent data that many of the most common can-
cers in high income countries are also the most common
in Africa, including prostate cancer, breast cancer and
cervical cancer [4, 5]. These research activities can in-
clude determining optimal screening and treatment
choices for prostate, breast, and cervical cancers; under-
standing the relative contributions of genetic, lifestyle,
and environmental factors in the development and pro-
gression of breast and prostate cancer in Africa; deter-
mining the influence of emigration on breast and
prostate cancer mortality comparing Africans in the
diaspora to indigenous Africans; and investigating the
Fig. 2 Countries with Cancer Research Projects as identified in the
AORTIC Cancer Research Registry (http://mendel2.med.upenn.edu:
8080/AfricaProject/MapView.jsp)
Fig. 3 Anticipated benefits of Cancer Research Development in Africa
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HPV types and other complimentary risk factors that are
peculiar to Africa. Other work will address unique needs
in Africa, including research on vaccine production
against HBV and HCV; development of new non-
invasive tests for biomarkers of hepatocellular carcinoma
using serological antibodies, proteomics and genomics
technology; investigate lung cancer patterns and other
causal risk factors apart from smoking in Africa; and
explore the role of genetics as an independent risk factor
for lung cancer in the African population. Thus, the mis-
sion of ACRA will be to promote inter- and intraregio-
nal collaborative research that will lead to improved
cancer control in Africa.
Going forward
The AORTIC vision for cancer research in Africa is to
provide knowledge that will inform cancer prevention
and control in Africa that will reduce the number of
deaths from cancer and improve the quality of life of
cancer patients, survivors and caregivers. Research
serves a critical need to generate knowledge around
which clinical, public health, and policy can be devel-
oped for cancer in Africa. As shown in Fig. 3, AORTIC
and its ACRA initiative will provide knowledge on im-
portant local issues, increase communication and dis-
semination of this knowledge, provide training in situ
for research capacity building in Africa, and will enhance
access to experts needed to develop this capacity. The
implementation of this plan includes development of
regional infrastructure that will foster cancer research;
increase the quality and quantity of research workforce
focused on cancer control in Africa; and promote and
support translational research throughout the cancer
control continuum across crosscutting issues, including
communications, surveillance, social determinants of
health, genetic testing, decision-making, dissemination
of evidence-based interventions, quality of cancer care,
epidemiology and measurement.
Authors’ contributions
JOO provided the template and wrote the initial manuscript, TRR reviewed
and revised the manuscript, DCS reviewed and contributed ideas to the
structure of the manuscript. All authors read and approved the final
manuscript.
Competing interests
All authors of this manuscript have roles in the African Organization for
Research and training in Cancer (AORTIC). DCS is the President-elect of
AORTIC and Co-Chair of the AORTIC research Committee, Tim Rebbeck is
the Chair of the AORTIC research Committee, and JOO is a Co-Chair of the
AORTIC research committee.
Author details
1AORTIC Research Committee, University of Ibadan, Ibadan, Nigeria. 2AORTIC
Research Committee, Walter Sisulu, Umtata, South Africa. 3International
Prevention Research Institute, Lyon, France. 4AORTIC Research Committee,
Dana Farber Cancer Institute and Harvard TH Chan School of Public Health,
Boston, USA. 5Department of Pathology, College of Medicine, University of
Ibadan, Ibadan, Nigeria.
Received: 10 October 2016 Accepted: 29 November 2016
References
1. Abayomi A, et al. African Strategies for Advancing Pathology (ASAP)
Strategic Plan, 2014–2019. Siena: African Pathologists; 2014.
2. Adesina A, et al. Improvement of pathology in sub-Saharan Africa. Lancet
Oncol. 2013;14(4):e152–7. ISSN 1474–5488. Disponível em: (http://www.ncbi.
nlm.nih.gov/pubmed/23561746).
3. Allemani C, Weir KH, Carriera H, Harewood R, Spika D, Wang X-S, Bannon F,
Ahn JV, et al. THELANCET-D-14-07220R1, Global surveillance of cancer
survival 1995–2009: analysis of individual data for 25,676,877 patients from
279 population-based registries in 67 countries (CONCORD-2); 2014.
4. Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11. Lyon: International Agency for
Research on Cancer; 2013.
5. Hsing AW, et al. High prevalence of screen detected prostate cancer in
West Africans: implications for racial disparity of prostate cancer. J Urol.
2014;192(3):730–5. ISSN 1527–3792. Disponível em: (http://www.ncbi.nlm.
nih.gov/pubmed/24747091).
6. Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
ISSN 1542–4863. Disponível em: (http://www.ncbi.nlm.nih.gov/pubmed/
21296855).
7. Mullan F, et al. Medical schools in sub-Saharan Africa. Lancet. 2011;
377(9771):1113–21. ISSN 1474-547X. Disponível em: (http://www.ncbi.nlm.
nih.gov/pubmed/21074256).
8. Plummer M, et al. Global burden of cancers attributable to infections in
2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609–16. ISSN 2214-
109X. Disponível em: (https://www.ncbi.nlm.nih.gov/pubmed/27470177).
9. Rebbeck TE. Handbook for Cancer Research in Africa. Brazzaville, Congo:
WHO Press; 2013.
10. Scheffler RM, et al. Forecasting the global shortage of physicians: an
economic- and needs-based approach. Bull World Health Organ. 2008;86(7):
516–523B. ISSN 1564–0604. Disponível em: (http://www.ncbi.nlm.nih.gov/
pubmed/18670663).
11. Scheffler RM. Estimates of health care professional shortages in sub-Saharan
Africa by 2015. Health Aff (Millwood). 2009;28(5):w849–62. ISSN 1544–5208.
Disponível em: (http://www.ncbi.nlm.nih.gov/pubmed/19661111).
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ogunbiyi et al. Infectious Agents and Cancer  (2016) 11:63 Page 6 of 6
